Lavender Synthopharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 1.00 M
as on 16-11-2024
- Company Age 3 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit 757.50%
(FY 2023)
- Ebitda 955.00%
(FY 2023)
- Net Worth 27.40%
(FY 2023)
- Total Assets 819.44%
(FY 2023)
About Lavender Synthopharma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹2.50 Cr.
Satish Mache, Atul Doke, Dnyandeo Pathare, and One other member serve as directors at the Company.
- CIN/LLPIN
U24299PN2021PTC203476
- Company No.
203476
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Aug 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Lavender Synthopharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anandrao Thombare  | Director | 14-Aug-2021 | Current |
| Satish Mache | Additional Director | 08-Jun-2024 | Current |
| Atul Doke | Director | 14-Aug-2021 | Current |
| Dnyandeo Pathare | Director | 14-Aug-2021 | Current |
Financial Performance of Lavender Synthopharma.
Lavender Synthopharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 757.5% increase in profit. The company's net worth Soared by an impressive increase of 27.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lavender Synthopharma?
In 2023, Lavender Synthopharma had a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lavender Laboratories Private LimitedActive 15 years 5 monthsSatish Mache, Atul Doke and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Feb 2024 | ₹2.50 Cr | Open |
How Many Employees Work at Lavender Synthopharma?
Lavender Synthopharma has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lavender Synthopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lavender Synthopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
